Planned USE SARS-CoV-2 Antigen Rapid Test is planned for the subjective recognition of SARS-CoV-2 Antigen in oropharyngeal swab and nasopharyngeal swab examples in vitro.
The SARS-CoV-2 is an encompassed β-Covid, round or curved molecule width of around 60 ~ 140nm, frequently
pleomorphic, clearly unique in relation to SARS-CoV and MERS-CoV in hereditary qualities. The principle clinical
signs incorporate fever, weakness and other foundational side effects, joined by dry hack, dyspnea, and so forth, which can quickly form into serious pneumonia, respiratory disappointment, intense respiratory pain disorder, septic shock, multi-organ disappointment, extreme corrosive base digestion issue, and even perilous. SARS-CoV-2 has been distinguished as the fundamental method for transmission through respiratory beads (wheezing, hacking, and so forth) and contact (picking nostril with the hand in touch with the infection, scouring eyes, and so on.).
SARS-CoV-2 is delicate to bright beam and hotness, and can be inactivated at 56℃ for 30 minutes and by fat dissolvable dissolvable like ethyl ether, 75% ethanol, chlorine sanitizer, peracetic corrosive and chloroform.
SARS-CoV-2 Antigen Rapid Test utilizes immuno-horizontal chromatography innovation for the subjective location of antigens. The colloidal gold particles named with the counter SARS-CoV-2 immune response 1 are fixed on the formation cushion.
The counter SARS-CoV-2 neutralizer 2 is bound on the “T” test line of nitrocellulose film. The Goat Anti-Mouse IgG is bound on the “C” control line of nitrocellulose layer. At the point when the grouping of SARS-CoV-2 in the example is higher than the base discovery limit, which can form with the counter SARS-CoV-2 immune response named with colloidal gold particles to shape a complex. This complex moves on the layer through hairlike activity until the test line, where it will be caught by the counter SARS-CoV-2 neutralizer 2 bound on the test line, framing “Au-Anti-SARS-CoV-2 neutralizer 1-(SARS-CoV-2) – Anti-SARS-CoV-2 counter acting agent 2 complex. These edifices are stored to show tone as the assurance of antigen positive, the remainder of hostile to SARS-CoV-2 neutralizer 1 marked with colloidal gold particles form with the Goat Anti-Mouse IgG and store to show tone as the assurance of nature of the “C” control line. At the point when the grouping of SARS-CoV-2 in the example is lower than the base discovery cutoff or no SARS-CoV-2, the buildings just store and show tone in the “C” control line.
1 test/unit, 5 tests/pack, 10 tests/unit, 20 tests/unit, 25 tests/unit, Test gadget: Mouse against SARS-CoV-2 monoclonal immune response,
Goat Anti-Mouse IgG polyclonal immunizer, Nitrocellulose layer.
• Extraction arrangement: Phosphate Buffer arrangement (0.01M, pH7.4±0.2)
• Extraction tube
• Bundle embed
•Expendable swabs (oropharyngeal swab or nasopharyngeal swab)
MATERIALS REQUIRED BUT NOT PROVIDED
REAGENT STORAGE AND STABILITY
Store the pack at 2-30°C/36-86°F, out of direct daylight, substantial for a long time. Try not to freeze the unit. The test gadget ought to
be utilized in no less than an hour subsequent to opening the foil pocket. For creation date and lapse date, kindly allude to the
1. Example assortment
Oropharyngeal swab example assortment:
The patient ought to shift their head somewhat vertically, open their mouth wide and utter a sound of “ah” to uncover both
pharyngeal tonsils. The expendable swab ought to be utilized to cross the tongue base. Wipe both pharyngeal tonsils back
what’s more, forward with slight power for no less than multiple times, and afterward wipe the back pharyngeal divider all over for at minimum
Nasopharyngeal swab example assortment:
Tenderly hold the patient’s head with one hand, cautiously embed the swab into the nostril and gradually dive deep along the
lower part of the lower nasal section. At the point when the highest point of the swab arrives at the back mass of the nasopharyngeal pit,
delicately pivot it for one round (stop briefly once reflex hack), and afterward leisurely eliminate the swab.
2. Example capacity
After treatment, the examples can be put away at room temperature (15-30℃) for as long as 24 hours, at 2-8℃ for up to 72
hours and at – 20℃ for as long as three years. The examples are permitted to be frozen and defrosted for three times.
Prior to utilizing the reagent, work it stringently as indicated by the bundle supplement to guarantee the precision of the outcomes.
1.The new examples will be treated with extraction arrangement as quickly as time permits after assortment, however no later than 1
hour after assortment.
2.Test gadget, test and instrument should be at room temperature (15~30℃) during the testing.
1. Eliminate one example extraction tube from the pack prior to testing.
2. Mark one example extraction tube or compose example number on it.
3. Place the marked example extraction tube in a rack in the assigned region of the work area.
4. Add the entire jug of extraction answer for the example remove tube.
5.Dip the swab head into the extraction arrangement in the extraction tube and turn the swab near the example
extraction tube divider for around 10 seconds or multiple times to disintegrate the examples in the arrangement however much as could reasonably be expected.
6.Squeeze the tip of the swab along the internal mass of the example extraction cylinder to keep the fluid in the cylinder as
much as could be expected, eliminate and dispose of the swab.
7.Tighten cylinder cover and hold on.
1.Before the recognition, the test gadget and the example are taken out from the capacity condition and adjusted to room
2.Tearing the bundling of the aluminum foil pocket, take out the test gadget, and put it on a level plane on the test table.
3.Vertically upset the example extraction tube (the extraction tube with handled examples), add 2 drops upward
into the example well of the test gadget.
4. The experimental outcomes ought to be deciphered inside 15 to 20 minutes, invalid If over 30 minutes.
5.Please decipher the outcome by visual assessment.
POSITIVE VALUE/LIMIT OF DETECTION
Positive worth/constraint of recognition: 1.7×102 TCID50/mL
Select the affirmed inactivated SARS-CoV-2 medium, (fixation 3.4×105 TCID50/mL), use inclination weakening
technique to figure out the infection medium to arrive at the basic worth of the location. Rehash the activity for 20 time and the
test result is positive for something like multiple times.
1.The SARS-CoV-2 Antigen Rapid Test is for in vitro symptomatic utilize as it were. The test ought to be utilized for the discovery of
SARS-CoV-2 Antigen in oropharyngeal swab and nasopharyngeal swab examples as it were.
2.This test unit must be utilized for the subjective discovery of SARS-CoV-2 antigens, and can’t decide the amount
of SARS-CoV-2 antigens in examples.
3.If the experimental outcome is negative and clinical side effects persevere. Continuing examining or utilize other testing is suggested
techniques for testing. An adverse outcome can’t block the chance of openness to or disease with SARS-CoV-2
4.The test aftereffects of the test units are for clinicians’ reference just, and ought not be utilized as the main reason for clinical
finding. The clinical administration of patients ought to be thoroughly viewed as in blend with their
side effects/signs, clinical history, other research facility tests and treatment reactions, and so on.
5.Due to the constraint of the identification reagent system, the restriction of location of this reagent is for the most part lower than that of nucleic corrosive reagents. Along these lines, the test work force ought to focus closer on the adverse outcomes and need to consolidate other test results to make a far reaching judgment. It is prescribed to utilize nucleic corrosive testing or on the other hand infection segregation and culture ID strategies to survey adverse outcomes which feel somewhat uncertain.
6. Investigation of the chance of bogus adverse outcomes:
(1) Unreasonable example assortment, transportation and handling, low infection titer in the example, no new example or
freezing and defrosting cycling of the example might prompt bogus adverse outcomes.
(2) The transformation of viral quality might prompt changes in antigenic determinants, which lead to adverse outcomes.
NOVATest Antigen Rapid Kit (NOVA Test)
|nCov-500||Atlas Link Technology||20 Tests||162 EUR|
NOVATest Antigen Rapid Test Kit (For Single Use) (NOVA Test)
|nCov-500-01||Atlas Link Technology||1T||162 EUR|
NOVATest IgG/IgM Antibody Rapid Test Kit (NOVA Test)
|UNCOV-40||Atlas Link Technology||40 Tests||115 EUR|
NOVATest VAPERON Neutralizing Antibody Rapid Detection Kit (NOVA Test)
|COVNA-503||Atlas Link Technology||20 Tests||Ask for price|
SARS-CoV-2 Antigen Rapid Test Kit
SARS-CoV-2 Antigen Rapid Test Kit
Accu-Tell COVID-19 IgG/IgM Rapid Test
|GEN-B352-20tests||Accu test||20 tests||283.2 EUR|
Accu-Tell COVID-19 IgG/IgM Rapid Test
|GEN-B352-40tests||Accu test||40 tests||385.2 EUR|
SARS-CoV-2 Rapid Antigen Test Nasal
|9901-NCOV-03G||Roche Diagnostics||25 Tests/Kit||112.8 EUR|
Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (Saliva)
2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)
|GEN-402-25tests||All test||25 tests||292.8 EUR|
Human Streptococcus Pneumoniae (SP) Antigen Rapid Test Kit
|abx092096-20tests||Abbexa||20 tests||477.6 EUR|
Avian Influenza Virus Antigen Rapid Test Kit (Colloidal gold)
|abx092015-40tests||Abbexa||40 tests||518.4 EUR|
Newcastle Disease Virus Antigen Rapid Test Kit (Colloidal gold)
|abx092016-40tests||Abbexa||40 tests||518.4 EUR|
Human Chlamydia Trachomatis Antigen Rapid Test Kit (Colloidal gold)
|abx092049-20tests||Abbexa||20 tests||276 EUR|
Avian Influenza H5 Virus Antigen Rapid Test Kit (Colloidal gold)
|abx092014-40tests||Abbexa||40 tests||585.6 EUR|
Avian Influenza H7 Virus Antigen Rapid Test Kit (Colloidal gold)
|abx092017-40tests||Abbexa||40 tests||518.4 EUR|
Melamine Rapid Test Kit
|abx092011-50tests||Abbexa||50 tests||444 EUR|
(3) The exploration on the SARS-CoV-2 has not been totally intensive; the infection might change and cause the
contrasts for best examining time (infection titer pinnacle) and testing area. Consequently, for similar patient, we can
gather tests from different areas or follow up for a very long time lessen the chance of bogus adverse outcomes.